Sustained relief

LACRISERT® acts like a slow-release, preservative-free, artificial tear.1,2

  • Prolongs the tear film breakup time
  • Provides ocular surface protection
  • Stabilizes and thickens the precorneal tear film
  • Provided greater reduction of moderate to severe dry eye syndrome symptoms and signs than artificial tears
The Data

LACRISERT® alleviates dry eye symptoms.

% Reduction in Symptoms at Visit 2 from Visit 1

Reduction in symptoms based on a multicenter, prospective, open-label patient registry (N=520)3. P<0.05 for all comparisons

 
LACRISERT®

Studies found that:

  • LACRISERT® can be used as adjunctive therapy for greater symptom reduction
  • Most patients remain on LACRISERT®
Additional Resources
 
Of patients who received LACRISERT®:

Felt that LACRISERT® improved the effectiveness of their existing therapy3,†

Remained on therapy 1 year later in a retrospective case study (n=80)1

References: (1.) Wander AH, Koffler BH. Extending the duration of tear film protection in dry eye syndrome: review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert. Ocul Surf. 2009;7(3):154-162. (2.) LACRISERT® [package insert]. Bridgewater, NJ: Bausch & Lomb. (3.) Koffler BH, McDonald M, Nelinson DS; for LAC-07-01 Study Group. Improved signs, symptoms, and quality of life associated with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry. Eye Contact Lens. 2010;36(3):170-176.

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

  • LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.
  • Instructions for inserting and removing LACRISERT® should be carefully followed.
  • If improperly placed, LACRISERT® may result in corneal abrasion. Because LACRISERT® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery.
  • The following adverse reactions have been reported, but were in most instances mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

To report suspected adverse reactions, contact Bausch & Lomb Incorporated at 1-800-321-4576 or FDA at 1-800-FDA-1088 or FDA.gov/medwatch.

Click here for full Prescribing Information

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions.

Important Safety Information

  • LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.
  • Instructions for inserting and removing LACRISERT® should be carefully followed.

Important Safety Information

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.